1
|
Vassilakopoulos T, Ferhanoglu B, Horowitz N, Mellios Z, Kaynar L, Zektser M, Symeonidis A, Piperidou A, Kalpadakis C, Akay OM, Atalar AC, Katodritou E, Leonidopoulou T, Papageorgiou S, Tadmor T, Gutwein O, Karakatsanis S, Ganzel C, Karianakis G, Isenberg G, Gainaru G, Vrakidou E, Palassopoulou M, Ozgur M, Siakantaris M, Paydas S, Tsirigotis P, Tsirogianni M, Hatzimichael E, Tuglular T, Chatzidimitriou C, Megalakaki E, Kanellias N, Zikos P, Koumarianou A, Gafter‐Gvili A, Angelopoulou M, Karmiris T, Gurion R. RITUXIMAB‐DOSE‐ADJUSTED EPOCH (R‐DA‐EPOCH) IN PRIMARY MEDIASTINAL LARGE B‐CELL LYMPHOMA (PMLBCL): REAL‐LIFE EXPERIENCE ON 190 PATIENTS FROM 3 MEDITERRANEAN COUNTRIES. Hematol Oncol 2021. [DOI: 10.1002/hon.76_2880] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
|
2
|
Vassilakopoulos T, Papageorgiou S, Michail M, Angelopoulou M, Kourti G, Kalpadakis C, Kotsopoulou M, Leonidopoulou T, Konstantinidou P, Kotsianidis I, Boutsis D, Michali E, Sachanas S, Terpos E, Karianakis G, Poziopoulos C, Vadikolia C, Pigaditou A, Vrakidou E, Anargyrou K, Symeonidis A, Stefanoudaki E, Hadjiharissi E, Papaioannou M, Gainaru G, Tsirogianni M, Katodritou E, Karmiris T, Variami E, Pappa V, Dimopoulos M, Roussou P, Panayitidis P, Konstantopoulos K, Pangalis G. PROGNOSTIC FACTORS (PFs) IN PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA (PMLBCL) TREATED WITH RITUXIMAB-CHOP (RCHOP) ± RADIOTHERAPY (RT). Hematol Oncol 2019. [DOI: 10.1002/hon.76_2630] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- T.P. Vassilakopoulos
- Dept of Haematology; National & Kapodistrian University of Athens; Athens Greece
| | - S.G. Papageorgiou
- 2nd Department of Internal Medicine and Research Institute; University General Hospital "Attikon"; Haidari Greece
| | - M. Michail
- Hematology; General Hospital of Nicosia; Nicosia Cyprus
| | - M.K. Angelopoulou
- Dept of Haematology; National & Kapodistrian University of Athens; Athens Greece
| | - G. Kourti
- 3rd Dept of Internal Medicine; National and Kapodistrian University of Athens; Athens Greece
| | - C. Kalpadakis
- Dept of Haematology; University of Crete; Heraclion Crete Greece
| | - M. Kotsopoulou
- Dept of Haematology; Metaxa Anticancer Hospital; Piraeus Greece
| | | | - P. Konstantinidou
- Dept of Haematology; Theagenion Anticancer Hospital; Thessaloniki Greece
| | - I. Kotsianidis
- Dept of Haematology; Democritus University of Thrace; Alexandroupolis Greece
| | - D. Boutsis
- Dept of Haematology; Navy Hospital Athens; Athens Greece
| | - E. Michali
- Dept of Haematology; Athens General Hospital, “Gennimatas; Athens Greece
| | - S. Sachanas
- Dept of Haematology; Athens Medical Center, Psychikon Branch; Athens Greece
| | - E. Terpos
- Dept of Therapeutics; National and Kapodistrian University of Athens; Athens Greece
| | | | - C. Poziopoulos
- Dept of Haematology; Metropolitan Hospital; Piraeus Greece
| | - C. Vadikolia
- Dept of Haematology; 424 Army Hospital; Thessaloniki Greece
| | - A. Pigaditou
- Dept of Haematology; Athens Medical Center; Marousi Greece
| | - E. Vrakidou
- Dept of Haematology; HyGEIA Hospital; Athens Greece
| | - K. Anargyrou
- Dept of Haematology; 251 Air Force Hospital; Athens Greece
| | - A. Symeonidis
- Dept of Haematology; University of Patras; Patras Greece
| | | | - E. Hadjiharissi
- 1st Dept of Internal Medicine; AHEPA University Hospital; Thessaloniki Greece
| | - M. Papaioannou
- 1st Dept of Internal Medicine; AHEPA University Hospital; Thessaloniki Greece
| | - G. Gainaru
- Dept of Haematology; HYGEIA Hospital; Athens Greece
| | - M. Tsirogianni
- Dept of Haematology; AGIOS SAVVAS Anticancer Hospital; Athens Greece
| | - E. Katodritou
- Dept of Haematology; Theagenion Anticancer Hospital; Thessaloniki Greece
| | - T. Karmiris
- Dept of Haematology; Evangelismos Hospital; Athens Greece
| | - E. Variami
- 1st Dept of Internal Medicine; National & Kapodistrian University of Athens; Athens Greece
| | - V. Pappa
- 2nd Department of Internal Medicine and Research Institute; University General Hospital "Attikon"; Haidari Greece
| | - M. Dimopoulos
- Dept of Therapeutics; National and Kapodistrian University of Athens; Athens Greece
| | - P. Roussou
- 3rd Dept of Internal Medicine; National and Kapodistrian University of Athens; Athens Greece
| | - P. Panayitidis
- 1st Propedeutic Dept of Internal Medicine; National & Kapodistrian University of Athens; Athens Greece
| | - K. Konstantopoulos
- Dept of Haematology; National & Kapodistrian University of Athens; Athens Greece
| | - G.A. Pangalis
- Dept of Haematology; Athens Medical Center, Psychikon Branch; Athens Greece
| |
Collapse
|
3
|
Kalpadakis C, Pangalis G, Konstantinou E, Vassilakopoulos T, Telonis V, Sachanas S, Tsirkinidis P, Moschogiannis M, Yiakoumis X, Siakantaris M, Tsaftaridis P, Iliakis T, Befani M, Kyrtsonis M, Dimitrakopoulou A, Boutsikas G, Korkolopoulou P, Kontopidou F, Koulieris E, Pontikoglou C, Ximeri M, Psylaki M, Roumelioti M, Rontogiannis D, Papadaki H, Panagiotidis P, Angelopoulou M. CLONAL B-CELL LYMPHOCYTOSIS OF MARGINAL ZONE ORIGIN (CBL-MZ): DESCRIPTION OF MAIN CLINICAL FEATURES, DISEASE EVOLUTION AND OUTCOME IN A SERIES OF 100 PATIENTS. Hematol Oncol 2019. [DOI: 10.1002/hon.38_2630] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
- C. Kalpadakis
- Department of Haematology; University Hospital, University of Crete; Heraklion Crete Greece
| | - G.A. Pangalis
- Department of Haematology; Athens Medical Center; Athens Greece
| | - E. Konstantinou
- Department of Haematology; University of Athens, Laikon General Hospital; Athens Greece
| | - T.P. Vassilakopoulos
- Department of Haematology; University of Athens, Laikon General Hospital; Athens Greece
| | - V. Telonis
- Department of Haematology; University of Athens, Laikon General Hospital; Athens Greece
| | - S. Sachanas
- Department of Haematology; Athens Medical Center; Athens Greece
| | - P. Tsirkinidis
- Department of Haematology; Athens Medical Center; Athens Greece
| | | | - X. Yiakoumis
- Department of Haematology; Athens Medical Center; Athens Greece
| | - M. Siakantaris
- Department of Haematology; University of Athens, Laikon General Hospital; Athens Greece
| | - P. Tsaftaridis
- Department of Haematology; University of Athens, Laikon General Hospital; Athens Greece
| | - T. Iliakis
- Department of Haematology; University of Athens, Laikon General Hospital; Athens Greece
| | - M. Befani
- Department of Haematology; University of Athens, Laikon General Hospital; Athens Greece
| | - M. Kyrtsonis
- 1st Department of Propedeutics; University of Athens, Laikon General Hospital; Athens Greece
| | - A. Dimitrakopoulou
- Immunology Laboratory; University of Athens, Laikon General Hospital; Athens Greece
| | - G. Boutsikas
- Department of Haematology; University of Athens, Laikon General Hospital; Athens Greece
| | - P. Korkolopoulou
- Department of Pathology; University of Athens, Laikon General Hospital; Athens Greece
| | - F. Kontopidou
- Second Department of Internal Medicine; Hippokrateio General Hospital, University of Athens; Athens Greece
| | - E. Koulieris
- Department of Haematology; Athens Medical Center; Athens Greece
| | - C. Pontikoglou
- Department of Haematology; University Hospital, University of Crete; Heraklion Crete Greece
| | - M. Ximeri
- Department of Haematology; University Hospital, University of Crete; Heraklion Crete Greece
| | - M. Psylaki
- Department of Haematology; University Hospital, University of Crete; Heraklion Crete Greece
| | - M. Roumelioti
- 1st Department of Propedeutics; University of Athens, Laikon General Hospital; Athens Greece
| | - D. Rontogiannis
- Department of Anatomic Pathology; Evangelismos General Hospital; Athens Greece
| | - H. Papadaki
- Department of Haematology; University Hospital, University of Crete; Heraklion Crete Greece
| | - P. Panagiotidis
- 1st Department of Propedeutics; University of Athens, Laikon General Hospital; Athens Greece
| | - M.K. Angelopoulou
- Department of Haematology; University of Athens, Laikon General Hospital; Athens Greece
| |
Collapse
|
4
|
Kyrtsonis MC, Koulieris E, Maltezas D, Tzenou T, Harding S, Kastritis E, Kafassi N, Bartzis V, Efthymiou A, Bitsanis K, Gavriatopoulou M, Terpos E, Kalpadakis C, K. Angelopoulou M, P. Vassilakopoulos T, R. Bradwell A, Beris P, A. Pangalis G, Panayiotidis P, A. Dimopoulos M. Prognostic Contribution of the New Immunoglobulin (Ig) Biomarkers (Freelite™ and Hevylite™) in Waldenstrom’s Macroglobulinemia (WM). ACTA ACUST UNITED AC 2012. [DOI: 10.5923/j.ajmms.20120206.05] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
|
5
|
Yiakoumis X, Pangalis GA, Kyrtsonis MC, Vassilakopoulos TP, Kontopidou FN, Kalpadakis C, Korkolopoulou P, Levidou G, Androulaki A, Siakantaris MP, Sachanas S, Andreopoulos A. Primary effusion lymphoma in two HIV-negative patients successfully treated with pleurodesis as first-line therapy. Anticancer Res 2010; 30:271-276. [PMID: 20150647] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/28/2023]
Abstract
Primary effusion lymphoma (PEL) is a rare non-Hodgkin's lymphoma (NHL) mostly occurring in HIV-positive patients. It is characterized by the development of effusion in one or more body cavities, with no tumor masses and a positive human herpes virus-8 (HHV8) status. It has a poor survival profile and no optimal treatment is yet defined. We report two HIV-negative, HHV8-positive patients with PEL of the pleural cavity who achieved a durable remission after pleurodesis with bleomycin and no systemic therapy. We also perform a review of the relevant literature regarding the clinical data, treatment, and survival of PEL in HIV-negative patients.
Collapse
Affiliation(s)
- X Yiakoumis
- Department of Haematology, Iatriko Athinon, Psychicon Branch, 1st Kyriakidou Str, P. Psychikon, 15452 Athens, Greece
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
6
|
Papadaki H, Koutala H, Velegraki M, Pyrovolaki K, Mavroudi I, Spanoudakis M, Mastrodimou S, Stavroulaki E, Psyllaki M, Kalpadakis C. P039 The diagnostic utility of bone marrow flow-cytometric immunophenotyping for the differential diagnosis of chronic idiopathic neutropenia from myelodysplastic syndromes. Leuk Res 2009. [DOI: 10.1016/s0145-2126(09)70119-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
7
|
Papadaki H, Velegraki M, Kozana A, Zamboulaki A, Kanellias N, Gvazava G, Kanellou P, Kaparou M, Psyllaki M, Kalpadakis C. C019 Functional abnormalities of neutrophils in patients with myelodysplastic syndromes. Leuk Res 2009. [DOI: 10.1016/s0145-2126(09)70057-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
8
|
Papadaki H, Mavroudi I, Psyllaki M, Pyrovolaki K, Papadaki V, Kalpadakis C, Mastrodimou S, Kaparou M, Kanellou P, Gvazava G. C027 The in vitro effect of SB-497115 (Eltrombopag) on megakaryopoiesis of patients with low/intermediate-1 IPSS myelodysplastic syndrome. Leuk Res 2009. [DOI: 10.1016/s0145-2126(09)70065-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
9
|
Kalpadakis C, Pangalis GA, Dimopoulou MN, Vassilakopoulos TP, Kyrtsonis MC, Korkolopoulou P, Kontopidou FN, Siakantaris MP, Dimitriadou EM, Kokoris SI, Tsaftaridis P, Plata E, Angelopoulou MK. Rituximab monotherapy is highly effective in splenic marginal zone lymphoma. Hematol Oncol 2007; 25:127-31. [PMID: 17514771 DOI: 10.1002/hon.820] [Citation(s) in RCA: 71] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
Abstract
Splenectomy has traditionally been considered as a standard first line treatment for splenic marginal zone lymphoma (SMZL) conferring a survival advantage over chemotherapy. However it carries significant complications, especially in elderly patients. The purpose of this retrospective study was to report our experience on the efficacy of Rituximab as first line treatment in 16 consecutive SMZL patients, diagnosed in our department. The diagnosis was established using standard criteria. Patients' median age was 57 years (range, 48-78). Prior to treatment initiation all patients had splenomegaly, nine had anemia, five lymphocytosis, five neutropenia and six thrombocytopenia. Rituximab was administered at a dose of 375 mg/m2/week for 6 consecutive weeks. The overall response rate was 100%. After treatment, all patients had a complete resolution of splenomegaly along with restoration of their blood counts. Eleven patients (69%) achieved a CR, three (19%) unconfirmed CR and two (12%) a PR. Among the complete responders seven patients had also a molecular remission. The median time to clinical response was 3 weeks (range, 2-6). Rituximab maintenance was given to 12 patients. Eleven of them had no evidence of disease progression after a median follow-up time of 28.5 months (range, 14-36), while two out of four patients who did not receive maintenance, relapsed 7 and 24 months after the completion of induction treatment. Median follow-up time for the entire series was 29.5 months (range, 15-81). No deaths were recorded during the follow-up period. Therapy was well tolerated. The present study demonstrates that rituximab is an effective treatment for SMZL and could be considered as a substitute or alternative to splenectomy.
Collapse
Affiliation(s)
- C Kalpadakis
- First Department of Internal Medicine, National Kapodistrian University of Athens, Laikon University Hospital, Athens, Greece
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|